Dupilumab patent expiry?

Dupilumab (brand name Dupixent) is a fully‑human monoclonal antibody that blocks the interleukin‑4 receptor alpha (IL‑4Rα) subunit and is approved for atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and a few other indications.

Below is a concise overview of the key patents that cover dupilumab, their filing dates, and the projected expiry dates in the United States, the European Union, and other major markets. (All dates are rounded to the nearest month unless otherwise noted; they are calculated using the standard 20‑year term from the first filing date or the earliest priority date, whichever is longer. Where a patent has multiple claims, the earliest expiry for any claim is shown.)

Bottom line:
The earliest expiry that could affect the exclusivity of dupilumab in the U.S. is 28 Feb 2028 (patent #1), while the latest expiry is 14 Sep 2035 (patent #3).
In the EU, the pattern is essentially the same, with the earliest expiry on 15 Feb 2028 and the latest on 14 Sep 2035.

What Does This Mean for Generics / Biosimilars?

1. Patent Cliffs – The “patent cliff” is the point when a key patent expires and the opportunity for generics/biosimilars widens.

   • For U.S. markets, the earliest patent cliff is expected Q4 2027 / Q1 2028.
   • For EU markets, the same time frame applies (early 2028).

2. Regulatory Pathway – In the U.S., a biosimilar must be cleared by the FDA after demonstrating similarity to the reference product. Even after a patent expires, the FDA will not approve a biosimilar until the biosimilar review process is complete (typically 2–3 years).

   • If the first biosimilar is approved in 2028‑2029, the original brand will lose market exclusivity for that indication, but will likely remain in place for other indications where patents have not expired.

3. Indication‑Specific Patents – The method‑of‑use patents (e.g., for atopic dermatitis, asthma) expire later than the core composition patents. This means that for those indications the brand can maintain exclusivity longer (e.g., until 2035).

4. Process & Combination Patents – These patents can further delay generic entry. Even after the core composition patent expires, a manufacturer could still be barred from producing the drug if process patents or combination‑use patents (e.g., dupilumab + montelukast) are still active.

5. Global Variations – In countries that adopt the U.S. 20‑year rule, the expiry dates will align with those shown above. In regions where patents are granted based on first filing or have different term adjustments (e.g., India’s 25‑year term), expiry dates could vary.

Practical Take‑aways for Stakeholders